Prime Medicine, Inc. Common Stock (PRME) is a biotechnology company listed on NASDAQ.
Latest reported PRME revenue for 2025-12-31 was $4.6M. Net income was -$201.1M. Revenue was up 55.3% from 2024-12-31 to 2025-12-31. PRME currently screens at market cap $570.8M.
Use this PRME page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the PRME quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the PRME SEC filings page. Lician reads the product cache first so this HTML stays unique to Prime Medicine, Inc. Common Stock even when a live quote feed is slow.
Latest cached year on this hub. Full PRME income, balance, and cash tables.